New antibody shows promise in early cancer trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Male or female patients aged ≥18 years. * Histologically and/or cytologically confirmed locally advanced or metastatic solid tumors refractory to standard therapy or for whom no standard therapy is available. * For Parts B and C, patients for whom anti-PD-1 or anti-programmed cell death ligand 1 (anti-PD-L1) are the SOC should have progressed on these therapies before being eligible for enrollment in Parts B and C. Patients cannot have received more than one anti-PD-1 or anti-PD-L1 based regimen. * Disease accessible for core needle biopsy both pre- and post-treatment with KBA1412. Biopsies will be mandatory for patients with melanoma and required for other tumor types depending on feasibility of obtaining tissue. * Measurable disease defined as: At least 1 lesion of ≥10 mm in the longest diameter for a non lymph node or ≥15 mm in the short-axis diameter for a lymph node that is serially measurable according to iRECIST using CT/MRI and will not be used for on-study paired biopsies. * ECOG Performance Status of 0-1. * Adequate hematologic, renal and hepatic function Exclusion criteria: * History of severe hypersensitivity reactions to other monoclonal antibodies. * Prior treatment with: * Any chemotherapy, anticancer small molecule therapy or investigational drug or device within 14 days or 5 half-lives (whichever is longer) prior to study treatment administration * Biological agents (including monoclonal antibodies) within 28 days prior to study treatment administration * Radiation, within 14 days prior to study treatment administration * Treatment with nitrosoureas or mitomycin C require a 42-day washout prior to study treatment administration * Anti-CD40 antibody or with FMS-like tyrosine kinase 3 ligand (FLT3L) * KBA1412. * Major surgery or significant traumatic injury within 4 weeks prior to study treatment administration. * Excluding the primary tumor leading to enrollment in this study, any other active malignancy (except for definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the bladder or cervix) within 24 months prior to study treatment administration. * Untreated primary central nervous system (CNS) malignancy. * Use of immunosuppressive medications within 4 weeks or systemic corticosteroids at doses exceeding 10 mg/ day (prednisone equivalent) within 2 weeks prior to study treatment administration. * Active autoimmune disease that has required systemic treatment within 2 years prior to study treatment administration. * Clinically significant cardiovascular disease, e.g., cerebral vascular accident/stroke or myocardial infarction, within 6 months prior to study treatment administration, unstable angina, congestive heart failure (New York Heart Association \[NYHA\] Class ≥III), or unstable cardiac arrhythmia requiring medication. * History of a major bleeding event (requiring a blood transfusion of \>2 units) not related to a tumor within 12 months prior to study treatment administration. * Ongoing Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 toxicity related to a previously administered anticancer agent with the following exceptions: * CTCAE Grade 2 neuropathy or alopecia * CTCAE Grade 2 immune-related endocrinopathy attributed to a checkpoint inhibitor and controlled with hormone replacement alone.